Antiemetic effect of low dose olanzapine in solid tumor chemotherapy

Chinese Journal of Cancer Prevention and Treatment

Volumn 20, Issue 7, 2013, Pages

  Lü, Ya Lei ^a   Liu, Wei ^a   Du, Yu Juan ^a   Feng, Li ^a   Wang, Yu Dong ^a   Wang, Long ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Nausea prevention and control; Neoplasms drug therapy; Vomit prevention and control

Indexed keywords

ANTINEOPLASTIC AGENT; OLANZAPINE;

ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84886892446     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Schwartzberg LS, Grunberg SM, Kris MG. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting[J]. Clin Adv Hematol Oncol, 2011, 9(Suppl 27): 1-14.
2. Hilarius DL, Kloeq PH, van der Wall E, et al. Chemotherapy-induced nausta and vomiting in daily clinical practice: a community hospital-based study[J]. Support Care Cancer, 2012, 20(1): 107-117.
3. Massa E, Astara G, Madeddu C, et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response[J]. Crit Re Oncol Hematol, 2009, 70(1): 83-91.
4. Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives[J]. J Natl Compr Canc Netw, 2012, 10(2): 149-157.
5. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial[J]. J Support Oncol, 2011, 9(5): 188-195.
6. Wickham R. Evolving treatment paradigms for chemotherapy-induced nausea and vomiting[J]. Cancer Control, 2012, 19(2 Suppl): 3-9.
7. Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting[J]. J Exp Clin Cancer Res, 2009, 28(1): 131.
8. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study[J]. Support Care Cancer, 2007, 15(11): 1285-1291.